Related Experiment Video

Updated: Feb 20, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.2K

Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States

Raxitkumar Jinjuvadia1, Augustine Salami1, Adrienne Lenhart1

  • 1Division of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, Michigan.

The American Journal of the Medical Sciences
|October 29, 2017
PubMed

Insights

Hepatocellular carcinoma (HCC) hospitalizations and costs significantly increased from 2002 to 2011. Despite decreased mortality and shorter hospital stays, the financial burden of HCC rose substantially.

Area of Science:

  • Hepatology
  • Oncology
  • Health Economics

Background:

  • Rising prevalence of hepatocellular carcinoma (HCC) necessitates understanding its impact.
  • Limited data exists on HCC-related hospitalizations and associated financial burden.
  • This study addresses the need for comprehensive data on HCC's economic and hospitalization trends.

Purpose of the Study:

  • To evaluate temporal trends in hepatocellular carcinoma (HCC)-related hospitalizations.
  • To assess the financial influence and economic burden of HCC hospitalizations.
  • To analyze changes in hospitalization rates, mortality, length of stay, and costs over time.

Main Methods:

  • Utilized the National Inpatient Sample database (2002-2011).
  • Identified patients diagnosed with HCC using International Classification of Diseases-Ninth Revision codes.
  • Calculated inflation-adjusted average charges per hospitalization.

Main Results:

  • HCC hospitalizations more than doubled from 24,024 (2002) to 50,609 (2011).
  • Inpatient mortality decreased from 13.5% to 9.9%, and average hospital stay shortened.
  • Inflation-adjusted costs per hospitalization increased by approximately 47%.

Conclusions:

  • Despite improved patient outcomes (reduced mortality and length of stay), hospitalizations for HCC continue to rise.
  • The financial burden associated with hepatocellular carcinoma (HCC) hospitalizations increased significantly between 2002 and 2011.
  • Healthcare systems must prepare for the growing economic impact of HCC.
Abstract

Keywords:
Financial burdenHepatocellular carcinomaHospitalizationsLiver cancerNational Inpatient Sample database

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.3K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
647
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
213
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
259